Skip to main content

Table 3 Baseline characteristics of HCV/HIV co-infected patients (HCV treated versus untreated)

From: German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients

Characteristics

Group A: HCV/HIV co-infected patients, treated (n = 36)

Group B: HCV/HIV co-infected patients, untreated (n = 52)

p-values

Age, mean (min./max.)

47 (26/64)

45 (27/61)

0.040

Sex, male/female (%)

26/10 (72/28)

40/12 (77/23)

0.617

Genotype, n (%)

   

 1

15 (42)

22 (42)

0.952

 2

2 (6)

1 (2)

0.356

 3

14 (39)

11 (21)

0.070

 4

1 (2)

1 (2)

0.791

 Unknown

4 (11)

17 (33)

0.020

Transmission of HCV, n (%)

   

 IVDU

21 (58)

37 (71)

0.212

 Transfusion

4 (11)

3 (6)

0.363

 Needlestick injury

0 (0)

0 (0)

n.a.

 Tatoo

0 (0)

0 (0)

n.a.

 Sex

1 (3)

3 (6)

0.508

 Unknown

10 (28)

9 (17)

0.241

CDC Classification, n (%)

   

 A1 – A3

13 (36)

10 (19)

0.005

 B1 – B3

9 (25)

7 (13)

0.168

 C1 – C3

9 (25)

22(42)

0.059

 Unknown

5 (13)

14 (26)

0.144

Liver biopsy, n (%)

7/36 (19)

5/52 (9)

0.186

 Fibrosis F3 – F4, n (%)

5/7 (71)

1/5 (20)

0.029

HCV RNA in IU/ml, mean (min./max.)

4800 000 (800/9 × 107)

4 713 000 (3/6 × 107)

0.965

CD4 Count absolute, mean

553,1

396,73

0.001

 CD4 Count > 200/μl, n (%)

25 (69)

21 (40)

0.007

 CD4 Count < 200/μl, n

2 (3,5)

16 (30)

0.004

 CD4 Count unknown, n (%)

7 (19)

15 (28)

0.317

CD4 Count relative, mean

27,9

22,2

0.001

CD4 Nadir in cells/μl, mean

208

194

0.689

CD4/CD8 Ratio, mean

0,67

0,49

0.001

HIV RNA in copy/ml, mean (minimum/maximum)

9 850 (3/16 × 104)

71 180 (3/12 × 105)

0.015

HIV Treatment, n (%)

29 (36)

0 (0)

n.a.

 NRTI, n (%)

20/29 (68)

n.a.

n.a.

 NNRTI, n (%)

18/29 (62)

n.a.

n.a.

 PI, n (%)

12/29 (41)

n.a.

n.a.

 Intregrase Inh., n (%)

2/29 (6)

n.a.

n.a.

 Entry Inh., n (%)

0 (0)

n.a.

n.a.